Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Trastuzumab in HER2+ Gastric/GEJ Cancer
NCT06572319Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Started Sep 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06572319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572319.